UCB announced a definitive agreement to acquire Candid Therapeutics, a clinical-stage biotechnology company focused on T-cell engager therapies for autoimmune ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE